WCN24-786 PHASE I DOSE ESCALATION STUDY OF SHR6508, A CALCIUM-SENSING RECEPTOR AGONIST, IN HEMODIALYSIS PATIENTS WITH SECONDARY HYPERPARATHYROIDISM

Secondary hyperparathyroidism (SHPT) is a chronic compensatory clinical manifestation, stimulated by long-term exposure to low blood calcium, low blood magnesium or high blood phosphorus. SHR6508, an allosteric modulator of calcium-sensing receptor, is developed to reduce parathyroid hormone (PTH) secretion among hemodialysis patients with SHPT. This first-inpatient study aimed to assess SHR6508 in Chinese patients with SHPT of chronic kidney disease on maintenance hemodialysis.